NOME welcomes four new high-potential Nordic life science startups

NOME (The Nordic mentor network for entrepreneurship) has engaged with four exciting life science startups. These companies come from a diverse range of technologies, personalized medicine in cancer, a diagnostic for joint damage, a stem cell therapy in diabetes and a company working in artificial intelligence to help diabetes patients manage their disease. NOME (The Nordic mentor network for entrepreneurship) – which is operated by Accelerace and funded by the Novo Nordisk Foundation – has engaged with four exciting life science startups.  These companies come from a diverse range of technologies, personalized medicine in cancer, a diagnostic for joint damage, a stem cell therapy in diabetes and a company working in artificial intelligence to help diabetes patients manage their disease. These NOME startups will now meet regularly with a team of experienced business mentors within their field, who will advise and support them to help them realize their goal of providing tools and therapies to patients. As a part of the program, NOME also provides a unique opportunity for the startups to participate in US a boot camp, where the companies get access to a US network of advisors who will help with strategy and introduce them to possible partners, investors and collaborators. Meet the NOME Mentors here: http://nome.nu/mentors Meet the new NOME Startups here: http://nome.nu Orthogenics (Norway) is leading in the field of joint replacement diagnostics. Orthogenics has identified a specific biomarker that is persistently detected in synovial tissue of the joint and correlates strongly with prosthesis failure. The aim is to generate a new product line for molecular diagnostics of prosthesis loosening. Read more on http://www.orthogenics.no/ SAGA Diagnostics (Sweden) is a personalized cancer medicine and disease monitoring company. Their tests quantify circulating tumor DNA (ctDNA) — a powerful new biomarker — to detect cancer, measure response to therapy, and decipher the cancer-specific DNA mutations that may be targetable with clinically approved drugs or therapies currently in clinical trials. Read more on http://sagadiagnostics.com/ Hedia (Denmark) is a personal diabetes-assistant, based on artificial intelligence that picks up patterns and habits of the individual diabetic patient.  Hedia has developed an app with a simple and intuitive design that will allow diabetics to enter; blood sugar levels, their meal, level of activity, to then get a suggested insulin dosage. Hedia learns from the data diabetics enter, so Hedia becomes smarter, to provide better advice when used regularly. Read more on http://hedia.dk/ PanCryos (Denmark) is a spin-out company arising from DanStem, University of Copenhagen, aiming to develop a next-generation stem cell-derived allogenic cell therapy (PanINSULA™) for Type 1 diabetes. PanCryos has assembled a team with experts in stem cell biology, islet transplantations, business and regulatory guidance and is currently funded by pre-seed funding from Novo Seeds and a KU POC grant. Read more on http://danstem.ku.dk/research1/semb_laboratory/ameri-project/ Get an overview of all the NOME participants here: http://nome.nu About NOME The Nordic Mentor Network for Entrepreneurship (NOME) is a Nordic and Transatlantic mentoring program that aims to improve the success rate of life science startup companies located in the Nordic countries. The mentor network consists of high profile life science executives that mentor best in class start-ups. NOME aims to position the Nordic region in a leading position in commercializing promising startup companies in the life sciences. NOME currently has +31 mentors and 11 enrolled startups. NOME is operated by Accelerace and funded by the Novo Nordisk Foundation. The initiative is represented in the Nordic region and the US through partnerships in Sweden, Norway, Finland and in North Carolina in the US. Read more on www.nome.nu]]>